Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to improve immune responses against Omicron subvariants, bivalent mRNA vaccines have recently been approved in several countries. In this study, we measure the capacity of plasma from vaccinated individuals, before and after a fourth dose of mono- or bivalent mRNA vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before and after the fourth dose, we observe a significantly better recognition and neutralization of the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been recently infected better recognize and neutralize the BQ.1.1 Spike, independently of the mRNA vaccine used, than donors who have never been infected or have an older infection. Our study supports that hybrid immunity, generated by vaccination and a recent infection, induces higher humoral responses than vaccination alone, independently of the mRNA vaccine used.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Vaccines - 11(2023), 2 vom: 21. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tauzin, Alexandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BQ.1.1 |
|---|
| Anmerkungen: |
Date Revised 01.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines11020242 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35357208X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35357208X | ||
| 003 | DE-627 | ||
| 005 | 20231226060318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines11020242 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM35357208X | ||
| 035 | |a (NLM)36851122 | ||
| 035 | |a (PII)242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tauzin, Alexandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to improve immune responses against Omicron subvariants, bivalent mRNA vaccines have recently been approved in several countries. In this study, we measure the capacity of plasma from vaccinated individuals, before and after a fourth dose of mono- or bivalent mRNA vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before and after the fourth dose, we observe a significantly better recognition and neutralization of the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been recently infected better recognize and neutralize the BQ.1.1 Spike, independently of the mRNA vaccine used, than donors who have never been infected or have an older infection. Our study supports that hybrid immunity, generated by vaccination and a recent infection, induces higher humoral responses than vaccination alone, independently of the mRNA vaccine used | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BQ.1.1 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a humoral responses | |
| 650 | 4 | |a hybrid immunity | |
| 650 | 4 | |a mRNA bivalent vaccine | |
| 700 | 1 | |a Benlarbi, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Medjahed, Halima |e verfasserin |4 aut | |
| 700 | 1 | |a Grégoire, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Perreault, Josée |e verfasserin |4 aut | |
| 700 | 1 | |a Gendron-Lepage, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Gokool, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Morrisseau, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a Arlotto, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Tremblay, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Kaufmann, Daniel E |e verfasserin |4 aut | |
| 700 | 1 | |a Martel-Laferrière, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Levade, Inès |e verfasserin |4 aut | |
| 700 | 1 | |a Côté, Marceline |e verfasserin |4 aut | |
| 700 | 1 | |a De Serres, Gaston |e verfasserin |4 aut | |
| 700 | 1 | |a Bazin, Renée |e verfasserin |4 aut | |
| 700 | 1 | |a Finzi, Andrés |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 11(2023), 2 vom: 21. Jan. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:2 |g day:21 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines11020242 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 2 |b 21 |c 01 | ||